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Further studies should evaluate multiple 
predispositions in heart failure prognosis
We read the article “The infl uence of acute pul-
monary embolism on early and delayed prognosis 
for patients with chronic heart failure” by Groma-
dziński et al. [1] with interest. The authors aimed 
to evaluate the potential impact of acute pulmonary 
embolism (APE) on early and long-term prognosis 
in patients with chronic heart failure (CHF). They 
concluded that patients with CHF and acute epi-
sode of PE are characterized by a higher 6-month 
total and cardiovascular mortality rate following 
discharge from hospital compared to patients 
hospitalized due to acute CHF decompensation. 
Heart failure is the most common disease with 
high mortality and morbidity rate in the worldwide 
[2]. Co-morbidities are important in patients with 
HF. Hepatic dysfunction may affect the use of 
treatments for HF [3]. On the other hand, drugs 
used to treat co-morbidities may cause worsening 
of HF (e.g. NSAIDs given for arthritis). After that, 
those used to treat co-morbidities may also interact 
with one another medication (e.g. beta-blockers 
and beta-agonists for chronic obstructive pulmo-
nary disease and asthma). Furthermore, some co-
-morbidities themselves may independently cause 
deterioration of HF (e.g. anemia) [4]. Additionally, 
impairment in basic activities of daily living and 
lack of social support may lead to worsening of 
HF [5]. Finally, we think that, besides the dosage, 
duration of the medication and HF age can also be 
associated with poor prognosis of HF.
Pulmonary embolism should be kept in mind 
as an increasing factor for mortality in HF. Because 
HF patients often have multiple predispose condi-
tions that amplify the risk of venous thromboem-
bolism because of venous stasis, increased blood 
viscosity, hypercoagulability, patients’ immobility, 
and more advanced age than that of the general 
population [6].. In the present study all patients with 
confi rmed APE were discharged from hospital on 
anticoagulant treatment recommended for at least 
3 months. The optimal duration of anticoagulant 
therapy can be modifi ed according to the risk of 
recurrent venous thromboembolism after stopping 
therapy. At this point, the existence and persistence 
of risk factors can provide important information to 
determine the treatment process. Three months of 
anticoagulation is suffi cient if PE is provoked by a re-
versible risk factor like surgery. However, 6 months 
or more prolonged anticoagulation is indispensable 
in the presence of persistent risk factors [7]. In this 
point of view, because HF is a permanent risk factor 
in patients with PE, the duration of therapy is the 
most important condition of affecting mortality rate. 
The classifi cation of  patients with PE as massive, 
submassive or nonmasif is very important factors 
of the early mortality and the treatment options 
and prognosis. 
In conclusion, PE alone is a potentially fatal 
disease without HF as presented in the current 
study. However, risk factors for HF prognosis are 
very complex and the pivotal roles of those risk 
factors deserve further large-scale prospective 
randomized clinical trials. 
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